After years of heartbreak, researchers have found an experimental treatment that can slow the progression of Huntington’s ...
People with Huntington’s disease often lose control over their voluntary movements, which can affect daily functioning more ...
Researchers announce breakthrough results for AMT-130, the first disease-modifying treatment for Huntington's disease, with ...
SAN DIEGO, Oct. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today presented new data from the open-label KINECT®-HD2 study demonstrating an established long-term safety profile ...
Victor Sung, M.D., director of the Division of Movement Disorders in the University of Alabama at Birmingham Department of ...
SAN DIEGO, June 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new patient-reported post-hoc data from the KINECT ®-HD study highlighting significant reductions ...
As well as slowing disease progression by 75 percent at 36 months, the scientists found that neurofilament light protein (NfL)—a biomarker of neuronal damage—levels in spinal fluid were lower in ...
Sex influences how genetic and age-related factors translate into clinical and neuroimaging trajectories in Huntington disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback